SCHEDULE: State Street Discloses 5.2% Stake in Catalyst Pharma

State Street Corporation has reported a 5.2% beneficial ownership stake in Catalyst Pharmaceuticals Inc. common stock as of September 30, 2025.

Summary

• State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in Catalyst Pharmaceuticals Inc.
• As of September 30, 2025, State Street Corporation beneficially owned 6,405,387 shares of Catalyst Pharmaceuticals Inc. common stock.
• This ownership represents 5.2% of the total class of securities.
• State Street Corporation holds shared voting power over 6,034,527 shares and shared dispositive power over all 6,405,387 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Subsidiaries involved in the beneficial ownership include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake by State Street Corporation is generally a neutral to slightly positive signal, indicating institutional interest and confidence in the issuer, Catalyst Pharmaceuticals Inc. It's a factual reporting of ownership rather than a performance update.

Positives

• A significant institutional investor like State Street Corporation holding a 5.2% stake can signal confidence in Catalyst Pharmaceuticals Inc.'s long-term prospects.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist position that could create uncertainty.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing reflects a standard disclosure by a large institutional asset manager, State Street Corporation, regarding its passive investment in a publicly traded pharmaceutical company. Such disclosures are common and indicate the ongoing portfolio management activities of major financial institutions within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by State Street Corporation may be viewed positively, indicating institutional confidence and potentially increasing liquidity or stability in the stock.
• Investors: Provides transparency regarding major institutional holdings, which can influence investment decisions.

Key Dates

Keywords

Catalyst Pharmaceuticals, State Street Corporation, Beneficial Ownership, Institutional Investment, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals